Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rhinitis and inhalant allergens

R Naclerio, W Solomon

    JAMA
    |December 13, 1997
    PubMed
    Summary
    This summary is machine-generated.

    Allergic rhinitis, affecting 20% of Americans, involves allergen exposure triggering immune responses. Management includes avoidance, medications like antihistamines and intranasal steroids, and immunotherapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

    Clinical and translational allergy·2019
    Same author

    Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

    Clinical and translational allergy·2017
    Same author

    ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle.

    Clinical and translational allergy·2017
    Same author

    Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

    Clinical and translational allergy·2016
    Same author

    MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation.

    Allergy·2015
    Same author

    Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs.

    The Journal of allergy and clinical immunology·2012
    Same journal

    Deescalation, Discontinuation, and Deimplementation Trials: Evaluating Whether and How to Do Less.

    JAMA·2026
    Same journal

    Surgical and Endoscopic Therapies for GERD.

    JAMA·2026
    Same journal

    The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

    JAMA·2026
    Same journal

    "Suturing": Love, Death, and Perfection's Limits.

    JAMA·2026
    Same journal

    What Is Low Back Pain?

    JAMA·2026
    Same journal

    From Silicon Valley to the Vatican-The Expanding Debate on AI Ethics.

    JAMA·2026
    See all related articles

    Area of Science:

    • Immunology
    • Allergy Research

    Background:

    • Allergic rhinitis impacts approximately 20% of the U.S. population.
    • Diagnosis relies on symptom patterns, physical exams, and IgE antibody testing.
    • Common triggers include pollens, fungi, animal allergens, and dust mites.

    Purpose of the Study:

    • To outline the pathophysiology of allergic rhinitis.
    • To describe diagnostic approaches.
    • To review management strategies for allergic rhinitis.

    Main Methods:

    • Review of diagnostic criteria for allergic rhinitis.
    • Analysis of the immunological mechanisms underlying allergic inflammation.
    • Evaluation of current therapeutic interventions.

    Main Results:

    Related Experiment Videos

    • Allergen exposure initiates rapid mast cell mediator release, followed by eosinophil and lymphocyte involvement.
    • T(H)2 cytokines, including interleukin-4 and -5, are key in orchestrating allergic inflammation.
    • Tissue changes from inflammation exacerbate symptoms and subsequent reactions.

    Conclusions:

    • Effective management necessitates allergen avoidance.
    • Intermittent allergic rhinitis symptoms are treated with antihistamines and decongestants.
    • Persistent symptoms may require intranasal steroids, with immunotherapy as an option for refractory cases.